Scientific data and AI company TetraScience announced on Monday that it has formed a collaboration with life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO).
The partners aim to accelerate AI across biopharma R&D and manufacturing by transforming scientific data into AI-native form and developing intelligent workflows at scale.
Through this collaboration, TetraScience will integrate Thermo Fisher's instrumentation and informatics solutions to further unlock the value of scientific data at scale. Alongside Thermo Fisher's AI capabilities, Tetra AI -- an intelligence layer that connects data and workflows to guide scientific decision-making and surface cross-domain insights -- will help power high-value use cases to improve reproducibility, throughput and scalability in therapies across R&D and manufacturing.
Patrick Grady, TetraScience CEO, said: "Scientific AI cannot be achieved on a foundation of fragmented systems and bespoke workflows. Operationalising AI requires large-scale, harmonised scientific data enriched with context specific to targeted use cases. That's how you deliver materially better scientific outcomes, and that is precisely what TetraScience enables. Our collaboration with Thermo Fisher Scientific will help biopharmaceutical organisations move faster and replace isolated processes with an AI-native scientific operating system that compounds in capability with every use -- powered by Tetra AI's ability to learn from each experiment and workflow."
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Futura Medical reports statistically significant female sexual function gains in WSD4000 study
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel